Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis.
Animals
Antibodies, Neutralizing
/ pharmacology
Bleomycin
Fibroblasts
/ pathology
Humans
Idiopathic Pulmonary Fibrosis
/ drug therapy
Interleukin-11
/ therapeutic use
Interleukin-11 Receptor alpha Subunit
/ metabolism
Lung
/ pathology
Mice, Knockout
Severity of Illness Index
Signal Transduction
Up-Regulation
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
25 09 2019
25 09 2019
Historique:
received:
21
11
2018
revised:
07
03
2019
accepted:
11
08
2019
entrez:
27
9
2019
pubmed:
27
9
2019
medline:
21
8
2020
Statut:
ppublish
Résumé
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease where invasive pulmonary myofibroblasts secrete collagen and destroy lung integrity. Here, we show that interleukin-11 (
Identifiants
pubmed: 31554736
pii: 11/511/eaaw1237
doi: 10.1126/scitranslmed.aaw1237
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Il11ra1 protein, mouse
0
Interleukin-11
0
Interleukin-11 Receptor alpha Subunit
0
Bleomycin
11056-06-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Department of Health
ID : CS-2013-13-017
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U120085815
Pays : United Kingdom
Informations de copyright
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.